Table 2.
Treatment and Outcome of 99 Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
| Variable | Total (N = 99) | Virus Negative (n = 61) | Virus Positive (n = 38) | P Value |
|---|---|---|---|---|
| Virological result, d | ||||
| Days of viral persistent positive | 16 (13–21) | 15 (12–19) | 19 (15–24) | .002 |
| Days from illness onset to diagnosis | 5 (2–7) | 5 (2.5–7.5) | 4 (1–6) | .05 |
| Fecal viral positive, No. (%) | 21 (21.2) | 9 (14.8) | 12 (31.6) | .000 |
| Treatment | ||||
| Antiviral treatment, No. (%) | 97 (97.9) | 61 (100) | 36 (94.7) | .15 |
| Days from illness onset to antiviral treatment start | 6 (4–8.5) | 6 (4–9.5) | 5.5 (3–7.8) | .15 |
| Two-antiviral combination therapy, No. (%) | 81 (81.8) | 50 (82) | 31 (81.6) | .96 |
| Corticosteroid treatment, No. (%) | 77 (77.8) | 47 (77) | 30 (78.9) | .82 |
| Days from illness onset to corticosteroid start | 8 (6–10) | 8 (6–10) | 7.5 (5–10) | .35 |
| Initial dosage of corticosteroid, mg/d | 60 (40–80) | 40 (40–80) | 60 (40–80) | .47 |
| Antibiotic treatment, No. (%) | 49 (49.5) | 27 (44.3) | 22 (57.9) | .19 |
| Days from illness onset to antibiotic start | 9 (6–13) | 9 (6–14) | 9.5 (5.5–11) | .29 |
| Intravenous immunoglobulin, No. (%) | 43 (43.4) | 19 (31.1) | 24 (63.2) | .002 |
| Days from illness onset to immunoglobulin use | 8 (6–11) | 8 (5–9) | 8 (6–12) | .44 |
| Severity score and outcome | ||||
| APACHE II | 6 (3–11) | 5 (2–8) | 9.5 (5–15) | .000 |
| ICU admission, No. (%) | 30 (30.3) | 10 (16.4) | 20 (52.6) | .000 |
| ICU length of stay, d | 7.5 (4–11) | 4 (3–5.8) | 8.5 (6.3–11) | .000 |
| Mechanical ventilation, No. (%) | 12 (12.1) | 2 (3.3) | 10 (26.3) | .001 |
| ECMO, No. (%) | 6 (6.1) | 0 | 6 (15.8) | .000 |
Data are presented as median (interquartile range) unless otherwise indicated. Values in boldface indicate statistical signifcance (P < .05).
Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit.